Ankylosing Spondylitis Axial Pain (Investigational Adjunct)

Краткая информация для пациента

Есть ли FDA-допуск для этого показания?

Not FDA-cleared for ankylosing spondylitis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational and only as an adjunct.

Какие доказательства существуют?

Tier C (investigational). No controlled trials exist for hirudotherapy in ankylosing spondylitis. The disease is a chronic inflammatory arthritis affecting the spine and sacroiliac joints, producing inflammatory back pain, morning stiffness, and progressive spinal ankylosis. Evidence-based management combines NSAIDs as first-line, biologic DMARDs (TNF-alpha inhibitors such as adalimumab/etanercept and IL-17 inhibitors such as secukinumab) for active disease despite NSAIDs, and a daily home exercise program emphasizing posture, range of motion, and cardiopulmonary conditioning.

Основные риски

• Bleeding from bite sites for 6 to 24 hours after detachment
• Bruising and tenderness over the paravertebral region for 5 to 14 days
• Infection risk if biologic therapy has caused immunosuppression
• Aeromonas hydrophila infection (especially risky in immunosuppressed patients)
• Allergic reaction to leech saliva
• Temporary worsening of back pain or new spasm
• Delay of biologic DMARD therapy or structured exercise, which have the strongest evidence
• Substitution of an adjunct for disease-modifying biologic therapy

Кому не следует это рассматривать

• Patients with biologic-induced neutropenia or active immunosuppression
• Patients in an active uveitis flare (urgent ophthalmology referral)
• Patients with spinal fracture or recent vertebral instrumentation
• Patients with active skin disease over the proposed placement site
• Patients on anticoagulants or with severe anemia
• Patients who have not engaged with structured exercise and standard DMARD therapy

О чём спросить врача

• Am I on a biologic DMARD (TNF or IL-17 inhibitor), and is my disease activity controlled?
• Am I doing the structured daily exercise program that is the cornerstone of management?
• Where exactly will the leech be placed, and how far from any spinal hardware?
• Am I currently immunosuppressed, and what is the infection-prevention plan?
• What is the realistic expected pain benefit, given no controlled trials exist?
• Has uveitis been excluded or managed?

Когда срочно обратиться за медицинской помощью

• New or worsening eye pain, photophobia, or vision loss (rule out uveitis)
• Fever above 38.0 C / 100.4 F or chills (especially on biologic therapy)
• Sudden severe back pain with leg weakness or numbness (rule out spinal pathology)
• Bowel or bladder dysfunction (cauda equina concern)
• Bleeding from a bite site lasting more than 24 hours
• Spreading redness, warmth, pus, or red streaks at any bite site